Mount Yale Investment Advisors LLC Takes $713,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Mount Yale Investment Advisors LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 9,172 shares of the medical device company’s stock, valued at approximately $713,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its position in DexCom by 0.7% in the second quarter. The Manufacturers Life Insurance Company now owns 289,824 shares of the medical device company’s stock worth $32,860,000 after purchasing an additional 1,998 shares during the last quarter. Ascent Group LLC boosted its holdings in shares of DexCom by 17.0% in the 2nd quarter. Ascent Group LLC now owns 7,367 shares of the medical device company’s stock worth $835,000 after purchasing an additional 1,072 shares during the period. Creative Planning raised its holdings in DexCom by 4.9% during the 2nd quarter. Creative Planning now owns 48,693 shares of the medical device company’s stock valued at $5,521,000 after buying an additional 2,271 shares during the period. NewEdge Advisors LLC lifted its position in DexCom by 18.3% in the second quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock worth $1,023,000 after buying an additional 1,393 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. increased its position in DexCom by 4.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after acquiring an additional 162 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Up 0.9 %

DexCom stock opened at $88.30 on Wednesday. The business has a fifty day moving average price of $79.73 and a 200-day moving average price of $76.70. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market capitalization of $34.49 billion, a price-to-earnings ratio of 52.87, a PEG ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DXCM. Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Raymond James reduced their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Citigroup increased their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada lowered their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.